TITLE

Designing clinical trials for continuous combined therapy

AUTHOR(S)
Viitanen, Antti
PUB. DATE
March 2000
SOURCE
Journal of the British Menopause Society;2000 Supplement, Vol. 6, p14
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents the design of clinical trials for continuous combined therapy. An association between unopposed exogenous oestrogens and the risk of endometrial cancer are detected in numerous epidemiological studies. The proliferative effect of oestrogens on the endometrium is counteracted by the administration of progestogen.
ACCESSION #
22658222

 

Related Articles

  • Assessment of generalisability in trials of health interventions: suggested framework and systematic review. Bonell, C.; Oakley, A.; Hargreaves, J.; Srange, V.; Rees, R. // BMJ: British Medical Journal (International Edition);8/12/2006, Vol. 333 Issue 7563, p346 

    The authors focus on the difficulty of generalizing the results of trials of health interventions in selected populations to policy and medical decision-making. HIV prevention trials targeting sexually active gay males are used to analyze the generalization of interventions. Clinical trials...

  • Cost Effectiveness of Lung-Volume—Reduction Surgery for Patients with Severe Emphysema.  // New England Journal of Medicine;5/22/2003, Vol. 348 Issue 21, p2092 

    Background: The National Emphysema Treatment Trial, a randomized clinical trial comparing lung-volume–reduction surgery with medical therapy for severe emphysema, included a prospective economic analysis. Methods: After pulmonary rehabilitation, 1218 patients at 17 medical centers were...

  • Date set for ACT India course.  // European Pharmaceutical Executive;Jun2007, p11 

    The article provides information on the 2007 Special Edition Short Course of "Applied Clinical Trials" entitled Conducting Clinical Trials in India, which will be held on June 26, 2007 at the Copthorne Tara Hotel in England. It is an intensive one-day seminar that is designed to provide an...

  • They're Dying to Get In. Bjerklie, David // Time International (South Pacific Edition);4/22/2002, Issue 15, p55 

    Discusses the difficulty of being able to participate in clinical trials in medicine. Benefits of the trials, including substantial doctor-patient interaction; Idea that it is not just the terminally ill who benefit from the attention, but also medically neglected or poorly informed subjects...

  • A Revised Approach to Early Trials. Priestley, Anthony // Applied Clinical Trials;Sep2008, Vol. 17 Issue 9, p90 

    The author reflects on the need to adopt new ways of designing and conducting early trials in the U.S. He suggests that data generated only in health volunteers can lead to erroneous conclusions about the likely behavior of a drug. He adds that ethical arguments may direct a company toward Phase...

  • How to Find a Trial. Smith, Ian K. // Time;11/22/1999, Vol. 154 Issue 21, p114 

    Offers information on patient enrollment in clinical drug trials. Researchers' need for patients as well as patients' need for treatment; Reasons adults do not participate in clinical drug trials; Where to locate trials. INSETS: Ace-ing It, by Janice M. Horowitz;Inside Information, by Janice...

  • Orphan drugs.  // Applied Clinical Trials;Sep2004, Vol. 13 Issue 9, p16 

    Reports on results of “Applied Clinical trials' online survey of priority issues in the field of clinical trials. Percentage of respondents who voted for recruitment; Increasing cost of drug development; Regulatory bureaucracy; Openness of trial data.

  • Nontoxicity Endpoints in Phase I Trial Design for Targeted, Non-Cytotoxic Agents. Korn, Edward L. // JNCI: Journal of the National Cancer Institute;7/7/2004, Vol. 96 Issue 13, p977 

    Examines why so few phase I trials for cytotoxic agents are using nontoxicity endpoints. Challenges in using these nontraditonal endpoints; Difficulty of defining the desired target effect; Practical difficulties in measuring these effects once they have been defined because of the lack of...

  • Directive Threatens Clinical Research in Europe, Critics Say. Rice, Mary // JNCI: Journal of the National Cancer Institute;7/7/2004, Vol. 96 Issue 13, p984 

    Reports that the new European Union directive on clinical trials was scheduled to be implemented in all member states by May 1, 2004 but many countries have not fully integrated the directive into clinical practice. Goal of simplifying and harmonizing clinical trials work by creating a single...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics